Outset Medical, Inc. 8-K

What Happened

• Outset Medical announced on June 14, 2026 that it entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, L.P. The amendment commits HCA to refresh its existing fleet by purchasing new Tablo Hemodialysis Systems starting in 2026 through the end of 2028. The agreement is reported to have an aggregate contract value, net of rebates and allowances, of approximately $40 million.

Key Details

• Amendment date/filing: entered June 14, 2026; the amendment is filed as Exhibit 10.1 to the 8-K (certain portions redacted).
• Committed spend: approximately $40 million in capital purchases (net of rebates and allowances) for new Tablo consoles and associated consumables.
• Timing: purchases to commence in 2026 and continue through the end of 2028; the agreement also establishes a purchase framework supporting potential future growth beyond current HCA hospitals using the Tablo in‑sourcing model.
• Guidance: Outset reiterated its previously issued 2026 guidance and said it will provide additional detail on the 2026 financial impact of the amendment later in the year once timing and ramp are clearer.

Why It Matters

• This is a multi-year, committed customer purchase that increases visibility for Outset’s device and consumables demand over 2026–2028 and could support future revenue growth if HCA expands use of the Tablo in more hospitals. The company has not changed its 2026 guidance yet and will quantify the financial impact when implementation timing is clearer, so investors should watch for follow-up disclosures that translate this commitment into timing of revenue and margin effects.